A PHASE Ib DOSE-ESCALATION AND DOSEEXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF VENETOCLAX IN COMBINATIONWITH ATEZOLIZUMAB, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LU
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
July 20, 2020
End Date
December 15, 2023
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
July 20, 2020
End Date
December 15, 2023